Navigation Links
BD Biosciences Launches New Cell Analyzer for Complex Multicolor Experiments in Disease and Drug Development Research
Date:6/1/2009

Special Order BD LSRFortessa(TM) Benchtop Flow Cytometry System Supports up to Five Lasers and 18 Colors Simultaneously

SAN JOSE, Calif., June 1 /PRNewswire/ -- BD Biosciences, a segment of BD (Becton, Dickinson and Company), announced today the launch of the new special order BD LSRFortessa(TM) cell analyzer, a powerful compact system that provides life science researchers with the ability to conduct complex multicolor flow cytometry experiments.

"Our special order research products program combines the knowledge gained from decades of working closely with leading researchers and excelling in manufacturing," said Jay Glasscock, President, Cell Analysis, BD Biosciences. "It allows us to work closely with customers to configure a BD LSRFortessa system that meets their exact specifications."

The BD LSRFortessa system offers power and flexibility in a benchtop footprint that is significantly smaller than the industry leading BD(TM) LSR II cell analyzer. It is the only compact cell analyzer that supports up to five lasers. Researchers can choose from 30 positions for detectors and 11 laser wavelengths and multiple power options to detect up to 18 colors simultaneously. Working with BD Biosciences' flow cytometry experts, laboratories can configure a system that meets their precise assay requirements.

"Space is at a premium in most research settings, leading many labs to compromise system power and performance because of space limitations," said Glasscock. "The new BD LSRFortessa system eliminates the need for that sacrifice by addressing researchers' growing analytical needs and helping to maximize lab space utilization at the same time."

The BD LSRFortessa system is the newest addition to the proven line of BD(TM) LSR cell analyzers. The original BD LSR II system supports up to seven lasers and has been the preferred tool of life science researchers worldwide working in core, academic, pharmaceutical and biotechnology laboratories.

For more information about the BD LSRFortessa cell analyzer, as well as the complete BD LSR product line, please visit: http://www.bdbiosciences.com/lsr.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit http://www.bd.com.


'/>"/>
SOURCE BD-Becton Dickinson
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
2. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
3. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
4. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
5. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
6. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
7. Anaptys Biosciences Raises Over $33 Million in Series B Financing
8. YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
9. Pressure BioSciences, Inc. Reports Third Quarter 2007 Financial Results and Provides Business Update
10. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
11. Regado Biosciences to Present at 19th Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... CA (PRWEB) , ... February 05, 2016 , ... ... to announce the addition of micro-needling services in their Napa Valley office. The ... founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are part of ...
(Date:2/5/2016)... ... ... US Sports Camps , official operators of Nike Yoga Camps, announces ... training. ChildLight Yoga Studio is centrally situated in the picturesque New England city of ... founder Lisa Flynn expresses her excitement, “We are thrilled to be partnering with US ...
(Date:2/5/2016)... ... ... Boar’s Head Brand®, one of the nation’s leading providers of premium delicatessen ... stress out of your party preparation – follow these easy, yet delicious recipes with ... game. , “The key to hosting a successful game-day party is creating a flavorful ...
(Date:2/5/2016)... CA (PRWEB) , ... February 05, 2016 , ... ... and founder of CitiDent, announces that it is now welcoming orthodontist, Dr. ... Cheng, CitiDent offers a complete range of oral health care, including general dentistry, ...
(Date:2/5/2016)... ... February 05, 2016 , ... On ... Rare Diseases, a continuing medical education (CME) event presented by the Association for ... kind—and a first for ACCORD, whose mission is to provide education, tools, and ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016 Summary Breast ... cancer and the most common cancer in women worldwide, ... disease exceedingly prevalent. The number of women diagnosed with ... but the number of deaths has declined due to ... treatment has been revolutionized in the past four decades, ...
(Date:2/4/2016)... Feb. 4, 2016 Mettler-Toledo International Inc. (NYSE: ... 2015.  Provided below are the highlights: , ... compared with the prior year.  Reported sales decreased 3% ... quarter. , Net earnings per diluted share as ... prior- year period.  Adjusted EPS was $4.65, an increase ...
(Date:2/4/2016)... 2016  Blueprint Medicines Corporation (NASDAQ: BPMC ... selective investigational kinase medicines for patients with genomically ... board of directors of Lonnel Coats , ... of industry-related experience. Jeffrey Albers ... strong strategic experience developing and commercializing numerous oncology ...
Breaking Medicine Technology: